Showing results (441-450 of 730) with videos related to
Sort By:
Pageof 73
The American Journal of Clinical Nutrition|June 27, 2014
Effects of homocysteine lowering with B vitamins on cognitive aging: meta-analysis of 11 trials with cognitive data on 22,000 individualsRobert Clarke, Derrick Bennett, Sarah Parish, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|January 15, 2014
Five-year safety evaluation of maraviroc in HIV-1-infected treatment-experienced patientsRoy M Gulick, Gerd Fatkenheuer, Robert Burnside, et al.The American Journal of Cardiology|August 16, 2018
Relation of Alcohol Consumption to Risk of Heart Failure in Patients Aged 65 to 84 Years With HypertensionBerhe W Sahle, Alice J Owen, Lindon M H Wing, et al.AIDS (London, England)|September 15, 2004
Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimenMarta Boffito, Michael Kurowski, Guido Kruse, et al.Patient Education and Counseling|April 24, 2024
How do general practitioners manage patient health literacy differences in cardiovascular disease prevention consultations? An interview studyShannon McKinn, Niamh Chapman, James E Sharman, et al.Neuroepidemiology|December 22, 2021
Optimal Measures for Primary Care Physician Encounters after Stroke and Association with Survival: A Data Linkage StudyDavid Ung, Yun Wang, Vijaya Sundararajan, et al.Gerontology|November 21, 2024
Age-Related Hearing Loss: A Cross-Sectional Study of Healthy Older AustraliansCarlene J Britt, Elsdon Storey, Robyn L Woods, et al.BMC Nephrology|April 17, 2013
Psychosocial factors in adults with chronic kidney disease: characteristics of pilot participants in the Tasmanian Chronic Kidney Disease studyCharlotte M McKercher, Alison J Venn, Leigh Blizzard, et al.Journal of Hypertension|October 5, 2019
Lack of a significant legacy effect of baseline blood pressure 'treatment naivety' on all-cause and cardiovascular mortality in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack TrialChau L B Ho, Monique Breslin, Enayet K Chowdhury, et al.Journal of the American College of Cardiology|February 9, 2013
Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)Manesh R Patel, Anne S Hellkamp, Yuliya Lokhnygina, et al.Pageof 73